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Background: Molecular stratification of bladder cancer has revealed gene signatures differentially expressed across
tumor subtypes. While these signatures provide important insights into subtype biology, the transcriptional
regulation that governs these signatures is not well characterized.
Methods: In this study, we use publically available ChIP-Seq data on regulatory factor binding in order to link
transcription factors to gene signatures defining molecular subtypes of urothelial carcinoma.
Results: We identify PPARG and STAT3, as well as ADIRF, a novel regulator of fatty acid metabolism, as putative
mediators of the SCC-like phenotype. We link the PLK1-FOXM1 axis to the rapidly proliferating Genomically Unstable
and SCC-like subtypes and show that differentiation programs involving PPARG/RXRA, FOXA1/GATA3 and HOXA/
HOXB are differentially expressed in UC molecular subtypes. We show that gene signatures and regulatory systems
defined in urothelial carcinoma operate in breast cancer in a subtype specific manner, suggesting similarities at the
gene regulatory level of these two tumor types.
Conclusions: At the gene regulatory level Urobasal, Genomically Unstable and SCC-like tumors represents three
fundamentally different tumor types. Urobasal tumors maintain an apparent urothelial differentiation axis composed
of PPARG/RXRA, FOXA1/GATA3 and anterior HOXA and HOXB genes. Genomically Unstable and SCC-like tumors
differ from Urobasal tumors by a strong increase of proliferative activity through the PLK1-FOXM1 axis operating in
both subtypes. However, whereas SCC-like tumors evade urothelial differentiation by a block in differentiation
through strong downregulation of PPARG/RXRA, FOXA1/GATA3, our data indicates that Genomically Unstable
tumors evade differentiation in a more dynamic manner.
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Urothelial carcinoma (UC) arises from the urinary blad-
der epithelium that consists of three cell layers, basal
cells, transiently amplifying cells and differentiated um-
brella cells. Basal cells typically express KRT5 and CDH3
(P-cadherin), whereas KRT20 and uroplakins are
expressed by umbrella cells. Upon injury, stromal signals
induce proliferation of basal cells that ultimately form
the more differentiated cell layers [1]. Key factors in
urothelial development and differentiation have been ex-
tensively studied during the last decade. These studies
have shown that nuclear receptors PPARG and RXRA,
as well as the transcriptional regulators FOXA1, TP63* Correspondence: mattias.hoglund@med.lu.se
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unless otherwise stated.and GATA family members govern different aspects of
the differentiation process [2]. Using molecular stratifica-
tion we have previously described three major subtypes of
urothelial carcinoma; Urobasal (A and B), Genomically
Unstable and SCC-like [3, 4]. Urobasal A (UroA) tumors
show papillary growth, good prognosis and frequent mu-
tation and expression of FGFR3. Urobasal B (UroB) tu-
mors are biologically and clinically progressed but
molecularly similar to UroA tumors [3, 4]. Genomically
Unstable (GU) tumors are undifferentiated, highly prolif-
erative and characterized by frequent E2F3/SOX4 amplifi-
cations, RB1 deletions, TP53 mutations and ERBB2
expression [4–6]. SCC-like (SCCL) tumors show en-
hanced expression of basal urothelial markers KRT5,
EGFR and CDH3, signs of keratinization and squamous
differentiation. Here we use publically available ChIP-Seql. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Eriksson et al. BMC Medical Genomics  (2015) 8:25 Page 2 of 15data on regulatory factor binding to link transcription fac-
tors to gene signatures defining molecular subtypes of UC.
We identify loss of PPARG and ADIRF, a novel regulator
of fatty acid metabolism, as well as upregulation of STAT3
expression, as putative mediators of the SCCL phenotype.
We link the PLK1-FOXM1 axis to the rapidly proliferating
GU and SCCL subtypes and show that differentiation pro-
grams involving PPARG/RXRA, FOXA1/GATA3 and
HOXA/HOXB are differentially expressed in UC molecu-
lar subtypes. We expand on the suggested similarities be-
tween UC and breast cancer [7], and show that gene
signatures and regulatory systems defined in urothelial
carcinoma operate in breast cancer in a subtype specific
manner suggesting similarities at the gene regulatory level
of these two tumor types.
Methods
Experimental design
The current study is based on the Lund 308 UC tumor
cohort for which gene expression data (GSE32894) and
tumor molecular subtype is available [3]. Informed con-
sent was obtained from all patients and the study was
approved by the Local Ethical Committee of Lund Uni-
versity in accordance with the Helsinki declaration. For
the present investigation, samples belonging to the “In-
filtrated” subtype were excluded as the gene expression
profile of this subtype is heavily compromised by infil-
trating immunological cells, leaving 131 UroA, 21 UroB,
85 GU and 29 SCCL cases. Processing and subtyping of
the Chungbuk UC dataset (n = 165) [8] was performed
as described previously [3]. Gene expression datasets
generated by The Cancer Genome Atlas Network
(TCGA) for bladder [9] (RNASeqV2, n = 223) and breast
[10] (Agilent 244 K, n = 547) were obtained through the
TCGA data portal. Whole-genome transcription factor
(TF) binding site data derived from chromatin immuno-
precipitation sequencing (ChIP-Seq) was obtained from
the ENCODE regulation super-track [11] via the UCSC
Genome Browser. Promoter regions (−5000 - +1000 bp
from the transcription start site (TSS)) of the longest
transcript of each RefSeq gene (23 645 genes at dataset
creation date 2013–01) were analyzed for TF ChIP-Seq
peaks using the “GenomicRanges” package in R [12].
CISTROME ChIP-Seq data was downloaded from the
Nuclear Receptor Cistrome Database [13] and mapped
to promoter regions in the same way. One additional
PPARG ChIP-Seq dataset was downloaded from Cistro-
meFinder portal [14]. ChIP-Chip data for 39 nuclear re-
ceptors and cofactors in MCF-7 cells generated by
Kittler et al. [15] was downloaded and their reported
50 kb TF-peak to gene-TSS assignments used. HOXA2
mouse ChIP-Seq data [16] was used to identify potential
human HOXA2 binding promoters. Gene symbols were
translated using bioDBnet [17]. Enrichment of HOXDNA motifs was analyzed with the SMART software
[18] using position weight matrices from TRANSFAC
Professional [19].Immunohistochemistry
Tissue microarrays (1.0 mm cores, 4 μm sections) were
analyzed with antibodies against CCNB1 (Y106, Epi-
tomics), EGFR (3C6, Ventana), FOXA1 (2F83, Abcam),
FOXM1 (C-20, Santa Cruz), GATA3 (D13C9, Cell Signal-
ing), phospho-HISTH3 (Ser10) (#9701, Cell signaling),
KRT5 (EP1601Y, Thermo Scientific), LAMA5 (4C7, Dako),
PLK1 (208G4, Cell signaling), PPARG (C26H12 Cell Sig-
naling), RXRA (F-1, Santa Cruz), STAT3 (124H6, Cell sig-
naling), phospho-STAT3 (Tyr705) (D3A7, Cell signaling).
Cores were evaluated as blinded digitalized image files. For
quantitatively staining markers (EGFR, FOXA1, GATA3,
KRT5, PPARG, RXRA, STAT3) a tumor cell score (TCS)
was defined as described in Sjödahl et al. [4]. For discrete
cellular labeling (CCNB1, FOXM1, PLK1, p-STAT3), frac-
tions of positive tumor cells was recorded. The mean
tumor cell score of core pairs from the same sample was
calculated. The number of cores evaluated for each marker
ranged from 480 to 524. Mitotic figures were identified by
the phospho-HISTH3 (Ser10) antibody and basal lamina
by anti-Laminin α-5 staining. When possible, lines were
drawn through the plane of the mitotic figure (in the dir-
ection of the cell division), and tangentially along the near-
est basal lamina (Photoshop CS5 version 12.1), and the
distance, in cell layers, to the basal membrane recorded. A
total of 416 mitoses from 112 different tumors were
analyzed.
Statistical analysis
Quality Threshold Clustering (QTC) was performed
with a sample jackknife correlation cut-off at 0.4, with a
minimum cluster size of 15 genes. Significance Analysis
of Microarrays (SAM) was performed with a FDR cut-
off set at 0 in all analyses [20]. SAM and QTC gene lists
are supplied in Additional file 1: Table S4. Literature
derived associations between gene lists and transcrip-
tional regulation was analyzed using GeneGo Meta-
Core™ (Thomson Reuters). Transcription factor binding
motif enrichment was examined both on the full pro-
moter sequence (−5000 - +1000 bp from TSS) as well
as DNaseI footprint filtered sequence [21]. In-silico en-
richment of ChIP-Seq binding was analyzed by two
methods; a one-tailed Fisher’s exact test and a resam-
pling based test examining both the number of bound
promoters as well as the total number of identified
ChIP-Seq peaks in a gene list compared to 100 000
randomly sampled gene lists of equal size. Only array
probes mapping to RefSeq genes were included for each
analysis.
Fig. 1 Genes downregulated in the SCC-like subtype. a Transcription factors strongly downregulated in the SCCL subtype included RXRA, PPARG, FOXA1,
GATA3, GATA2, TBX2, TBX3 and ELF3. b Enrichment of RXRA, PPARG, FOXA1 and GATA3 binding in the SCCL-down genes. (red, query signature; blue, 105
randomly sampled gene lists of equal size to the query signature). c Colocalization of RXRA, PPARG, FOXA1 and GATA3 binding events in SCCL-down
genes using the Kittler data set in a ±1000 bp window centered on the first factor in each subpanel. d A 42 gene QTC cluster, enriched for the GO term
lipid metabolism included the transcription factors PPARG, FOXA1, GATA3, TBX3 and the adipogenesis regulatory factor ADIRF. e Downregulated genes
involved in lipid metabolism (n= 233) in the TCGA BC basal-like subtype
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Coordinated downregulation of a urothelial
differentiation module in the SCC-like UC subtype
We applied SAM analysis to identify significantly downregu-
lated genes in the SCCL subtype (SCCL-down, n= 829
genes). To screen for possible upstream regulatory factors
we analyzed the SCCL-down gene list using GeneGO Meta-
Core, which revealed a regulatory association between the
downregulated genes and the PPARG and RXRA transcrip-
tion factors/nuclear receptors, both downregulated in the
SCCL subtype. PPARG and RXRA cooperate as heterodi-
mers and induce differentiation though the transcription
factors ELF3, FOXA1 and members of the GATA transcrip-
tion factor family [22, 23] (Additional file 2: Figure S1). The
PPARG, RXRA, GATA2, GATA3, FOXA1 and ELF3 tran-
scription factors genes were among the most downregulated
in the SCCL-down list (Fig. 1a, Additional file 2: Table S2).
We mapped ChIP-Seq and ChIP-Chip derived transcription
factor binding sites obtained from ENCODE, CISTROME
and Kittler et al. to all RefSeq gene promoters in order to
calculate in-silico ChIP-Seq binding enrichment. The SCCL-
down gene list was highly enriched for RXRA, PPARG,
FOXA1 and GATA3 binding sites with p-values ranging
from 10−4 to 10−18 (Additional file 2: Table S1A), corrobo-
rated by the resampling-based test (Fig. 1b). ChIP-Seq peak
calls indicated binding of at least two of these factors in a
majority (60 %) of SCCL-down promoters (Additional file 2:
Figure S2), as well as spatial clustering of binding sites
(Fig. 1c). The SCCL-down genes were also enriched for
RARA and RARB binding sites. While the mRNA levels of
the RAR genes did not vary between subtypes, we observed
SCCL specific downregulation of ALDH1A2 and overex-
pression of CYP26B1, involved in synthesis and degradation
of the retinoid RAR ligands, respectively (Additional file 2:
Figure S3). We used bootstrap hierarchical clustering [24] to
identify the SCCL subgroup (n = 71) of tumors in The Can-
cer Genome Atlas Network (TCGA) bladder cancer data
(Additional file 2: Figure S4), and derived an independent
list of SCCL downregulated genes. We found a significant
overlap between the two SCCL-down lists (581 of 829
genes). The transcription factors PPARG, FOXA1, GATA3,
GATA2 and ELF3 ranked among the top downregulated
genes also in the TCGA SCCL subgroup (Additional file 2:
Figure S4, and Table S2). RXRA was not among the signifi-
cant genes as expression of RXRA is a characteristic of low
stage tumors absent in the TCGA dataset (Fig. 1a). In-silico
ChIP-Seq analysis showed strong enrichment for RXRA,
PPARG, FOXA1 and GATA3 binding also at TCGA-SCCL-
down gene promoters (Additional file 2: Table S1B).
PPARG regulated lipid metabolic genes are
downregulated in the SCC-like UC subtype
The SCCL-down list was highly enriched for genes an-
notated with “lipid metabolism” (116 of 829, p < 10−24).In-silico ChIP-Seq analysis of the promoters revealed a
strong enrichment for PPARG binding (40 % bound, p <
10−6), in line with PPARG involvement in lipid metabol-
ism [25]. Unsupervised quality threshold clustering (QTC)
identified a tightly correlated cluster of genes (n = 42)
enriched for GO term “lipid metabolic process” (p < 10−5).
This cluster was strongly downregulated in the SCCL sub-
type (Fig. 1d) and included the transcription factors
PPARG, TBX3, FOXA1, GATA3 and ADIRF (c10orf116).
ADIRF promotes adipocyte differentiation by acting up-
stream of and inducing PPARG expression [26]. This hier-
archy of regulation is supported by the finding that the
ADIRF promoter region does not contain any PPARG
ChIP-Seq binding sites. We were unable to analyze ADIRF
binding as ChIP-Seq data has not been generated for this
factor. ADIRF was also the top ranking transcriptional
regulator in the TCGA SCCL-down gene lists, supporting
a role in urothelial carcinoma.
A STAT3 regulated gene signature is upregulated in the
SCC-like UC subtype
We identified a tightly correlated QTC cluster
(“Keratinization”) upregulated in SCC-like UC that in-
cluded KRT5, KRT6A, KRT6B, KRT6C, KRT14 and
KRT16 (Fig. 2a). In-silico ChIP-Seq analysis of promoters
revealed strong enrichment of STAT3 and FOS binding
(72 % and 81 % bound respectively, both p < 10−4). We
performed a SAM analysis to derive an expanded list of
genes upregulated in SCC-like UC (SCCL-up, n = 1085
genes), and found strong enrichment of STAT3 binding
at SCCL-up gene promoters (44 % bound, p < 10−25),
corroborated by the resampling-based analysis (Fig. 2b).
We also detected enrichment of FOS (57 % bound, p <
10−21), MYC (57 % bound, p < 10−21), and CEBPB (60 %
bound, p < 10−11) binding at SCCL-up gene promoters.
Binding peaks for these transcription factors exhibited a
high degree of spatial overlap (Fig. 2c). The high density
of STAT3 binding sites within KRT5 and KRT6 pro-
moters links STAT3 activation with KRT5/6 expression
(Fig. 2d). SCCL tumors display nuclear protein expres-
sion of phospho-STAT3 showing that STAT3 is activated
in these tumors. In addition, EGFR that both activates
and interacts with STAT3 [27, 28] showed increased ex-
pression in the SCCL subtype (Fig. 2e-f ).
Similarities between SCC-like UC, basal-like breast cancer
and squamous cell carcinoma of the lung
We extracted a breast cancer (BC) basal-like down gene
signature from breast cancer TCGA data. This signature
included FOXA1, GATA3, ESR1, as well as ADIRF, as
high ranking genes (ranks 1, 11, 13 and 139, respectively,
out of 3638 genes) (Additional file 2: Table S2). ChIP-
Seq data revealed that BC basal-like downregulated gene
promoters were highly enriched for RXRA, PPARG,
Fig. 2 (See legend on next page.)
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Fig. 2 Genes upregulated in the SCC-like subtype. a A 23 gene QTC cluster containing multiple genes involved in keratinization including KRT5,
KRT6A-C and KRT14. EGFR expression is increased in the SCCL subtype. b Enrichment of STAT3 binding in SCCL-up genes (red, query signature;
blue, 105 randomly sampled gene lists of equal size to the query signature). c Colocalization of FOS, MYC and CEBPB with STAT3 binding sites in
the promoters of SCCL-up genes, using ENCODE ChIP-Seq data, window centered on STAT3. d STAT3, FOS, MYC and CEBPB binding sites in the
promoters of the KRT5 and KRT6 genes. e Heat map indicating the EGFR and pSTAT3 IHC staining scores, respectively. f IHC sections stained for
EGFR (top) and pSTAT3 (bottom) showing characteristic staining patterns of the bladder cancer subtypes. g Expression pattern of the bladder
derived keratinization QTC cluster genes and EGFR in the TCGA breast cancer dataset
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file 2: Table S1C). To extend this comparison we identi-
fied 664 genes that were downregulated in SCCL UC
and basal-like BC in the TCGA data sets. Binding of
PPARG, RXRA and ESR1 to the respective promoters
were highly significant (p-values 10−4, 10−7 and 10−10, re-
spectively), and exhibited spatial overlaps at promoters
(Fig. 3a-c). Prat et al. [29] highlighted similarities be-
tween basal-like BC and lung squamous cell carcinoma
and defined a gene signature shared between the two
cancer types. Of the 300 downregulated genes in this
shared signature, FOXA1, GATA3, and ESR1 were among
the top ranking transcription factors (ranks 10, 3 and 1,
respectively). These observations support downregula-
tion of the FOXA1 and GATA3 transcription factors as
important components in maintaining a basal/SCC-like
phenotype. Furthermore, the breast cancer basal-like
down genes were enriched for “lipid metabolic process”
(p < 10−5, n = 233), indicating that analogous processes
are inhibited in both SCCL UC and basal-like BC
(Fig. 1e). Overexpression of the correlated keratinizationFig. 3 Promoter binding overlap in UC and BC downregulated genes. a Co
regions of the 664 genes downregulated both in the UC TCGA SCCL and t
dataset. b Co-occurrence of FOXA1, RXRA, GATA3 and ESR1 binding in pro
SCCL and the BC TCGA basal-like subtypes. Co-occurrence derived from th
the promoters of the 664 genes downregulated in both the bladder SCCL
and ESR1 (right) binding eventsQTC genes and EGFR was observed also in basal-like
BC (Fig. 2g), further emphasizing the similarity between
the respective UC and BC subtypes.
A PLK1-FOXM1 cell cycle axis operating in the GU and
SCC-like UC subtypes
We identified a tightly coordinated QTC cluster (“Late
Cell Cycle”) of 129 proliferation associated genes highly
expressed in GU and SCCL tumors (Fig. 4a). This cluster
included several transcriptional regulators, e.g., FOXM1,
E2F2, EZH2, E2F7 and BRCA1 (Fig. 4a). Furthermore,
GeneGO MetaCore analysis of the gene list suggested a
link to transcription factors E2F1, E2F2, E2F3, MYC,
MYBL2 and FOXM1 (all p < 10−8). ChIP-Seq analysis
showed strong enrichment of DREAM complex [30]
members FOXM1 (76 % bound, p < 10−35, Fig. 4b), E2F4
(p < 10−35), and MYBL2 (p < 10−31) as well as other cell
cycle regulatory factors e.g., E2F1 (p < 10−30), NFYA (p <
10−29), and NFYB (p < 10−30) (Additional file 2: Table
S3). ChIP-Seq peaks for these factors all exhibited a high
degree of spatial overlap with the FOXM1 peaks (Fig. 4c).-occurrence of FOXA1, RXRA, GATA3 and PPARG binding in promoter
he BC TCGA basal-like subtypes. Co-occurrence derived from the Kittler
moter region of the 664 genes downregulated both in the UC TCGA
e Kittler dataset. c Co-localization of binding events. ChIP-Seq peaks in
and breast basal-like subtypes, centered on PPARG binding events (left),
Fig. 4 FOXM1 regulated genes in UC. a A QTC cluster of 129 genes linked to the late cell cycle including the transcription factors FOXM1, among
others. PLK1 mRNA expression levels are indicated. b Enrichment of FOXM1 promoter binding in late cell cycle QTC genes (red, query signature;
blue, 105 randomly sampled gene lists of equal size to the query signature). c Transcription factors associated with cell cycle regulation and the
DREAM complex colocalizes with FOXM1 binding events in the late cell cycle QTC gene promoters. d Heat map indicating the percentage of
FOXM1 and PLK1 positive tumor nuclei in TMA cores. e FOXM1 (top) and PLK1 (bottom) stained sections of representative tumors across the UC
subtypes. f The UC derived late cell cycle gene cluster in the breast cancer TCGA gene expression dataset
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mediated by PLK1 [31]. FOXM1 and PLK1 protein ex-
pression showed overlapping (IHC) nuclear labeling pat-
terns and were highly correlated across the data (r = 0.75,
p < 10−15) (Fig. 4d-e). The UC derived FOXM1 late cell
cycle signature showed coordinated expression in the BC
TCGA data with Luminal A showing low and Luminal B,
HER2-enriched and basal-like high expression (Fig. 4f).
Urobasal A tumors express RXRA, PPARG, FOXA1 and
GATA3 at the protein level
We explored protein expression of the differentiation
factors RXRA, PPARG, FOXA1 and GATA3 using IHC
(Fig. 5a and Additional file 2: Figure S5). Protein expres-
sion correlated with mRNA levels and was high in UroA,
intermediate in UroB and GU and absent in SCCL.
Using lack of protein expression (Tumor Cell Score <
0.5, with a range of 0–3) of at least one member of the
circuit as an indication of a non-functional pathway, the
full complement of the circuit was maintained to larger
extent in UroA compared to the rest (p < 10−6, Fishers
exact test), as well as when compared with GU only (p <
10−3) (Fig. 4a). We then investigated mRNA expression
of fatty acid binding proteins (FABP4 and FABP5) andFig. 5 UroB, GU and SCC-like tumors lose transcription factors involved in
lipid-binding proteins. a Heat map illustrating nuclear IHC staining for trans
individual transcription factors (top). Loss of any transcription factor (IHC sc
mRNA expression across UC subtypes. Red bars up, expression above medi
FABP4/5 and CRABP2 mRNA levels, respectivelycellular retinoic acid-binding protein (CRABP2) specific-
ally. These proteins are involved in shuttling of lipophilic
ligand compounds and retinoic acid (RA) to the PPAR
and RAR nuclear receptors [32]. UroA cases showed
high expression of FABP4 and FABP5 and low expres-
sion of CRABP2 mRNAs, whereas the reverse was ob-
served for UroB, GU and SCCL cases (Fig. 5b). The
FABP4/5 and CRABP2 gene expression ratios, crucial for
ligand shuttling and response [33, 34], show an even
stronger contrast between UroA and the remaining
UroB, GU and SCCL subtypes (Fig. 5c).
Urobasal A tumors express anterior HOXA and HOXB
genes
We have previously documented a differentiation-related
switch in DNA methylation states between anterior
(HOXA1-7) and posterior (HOXA9-13) HOXA genes
[35]. To explore the differential HOX-gene expression in
the context of UC molecular subtypes, we assigned each
tumor a HOX-score based on the balance of anterior
HOXA and HOXB versus posterior HOXA gene expres-
sion (Additional file 2: Figure S6). Rank-ordering tumors
by HOX-score clearly separated tumors expressing an-
terior HOXA and HOXB genes (high HOX-scores) fromurothelial differentiation and have altered expression of intracellular
cription factors involved in urothelial differentiation. IHC scores for the
ore <0.5) indicated with blue (bottom). b FABP4, FABP5 and CRABP2
an; green bars down expression below median c The ratio between
Fig. 6 A HOXA/HOXB switch in urothelial carcinomas. a Expression of HOXA and HOXB genes. Cases arranged according to HOX-switch score.
The HOXA2-A6/HOXB2-B8 expressing group consists mainly of Urobasal A tumors and is enriched for grade G1 tumors. Anterior HOXA b and
HOXB c gene clusters show frequent binding sites for RXRA, PPARG, FOXA1, GATA3 and for RARA. d The expression of HOXA2 binding genes
across the Lund dataset. Bar above heat map indicates HOX-switch score (red, high score; green, low score). e The expression of HOXA2 binding
genes across the Chungbuk cohort. Bar above heat map indicates HOX-switch score (red, high score; green, low score)
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scores) genes (Fig. 6a). Tumors with high HOX-scores
were of low grade and strongly enriched for the UroA
subtype (Fig. 6a). Similar patterns of differential HOXA/
HOXB expression were not observed in the TCGA BC
data (Additional file 2: Figure S7A). ChIP-Seq analysis
showed frequent RXRA, PPARG, FOXA1, GATA3 and
RARA binding within the anterior HOXA and HOXB
locus (Fig. 6b-c). As we were unable to find ChIP-Chip
or ChIP-Seq data for human anterior HOXA genes, we
made use of HOXA2 ChIP-Seq data generated in mouse
[16], and translated the list of mouse target genes to hu-
man orthologs. Mapping of TRANSFAC transcription
factor binding motifs revealed substantial enrichment ofFig. 7 Cell divisions show preferential localization near the basal lamina an
Immunohistochemical stainings of five Urobasal A cases (1–5) and two GU
of five Urobasal A cases (1–5) and two GU/SCCL cases (6–7) with anti-PLK1
two GU/SCCL cases (6–7) with antibodies for histone H3 phosphorylated a
angles relative cell layer in low-grade vs. high-grade tumors and in Urobas
e Median observed basal cell division angles in low-grade vs. high-grade tu
distribution of medians from 104 randomly generated sets of angles of equHOX motifs across the human ortholog promoters. We
used SAM to derive a list of genes upregulated in tu-
mors with a high HOX-score and quantified the overlap
with the translated HOXA2 target gene list. Of 672 up-
regulated genes, 143 (23 %) were putative HOXA2 tar-
gets in mouse, a significant enrichment (p < 10−11,
Additional file 1: Table S4). The expression pattern of
human ortholog HOXA2 target genes mirrored the
HOX-score with high expression levels in UroA cases,
intermediate levels in UroB and low expression in GU
and SCCL cases (Fig. 6d). The HOX-score and HOXA2
gene signature expression patterns were recapitulated in
an independent UC dataset (Fig. 6e, Additional file 2:
Figure S7B). HOXA2 target genes were enriched for GOd to close to 90 ° in low grade Urobasal tumors. a
/SCCL cases (6–7) with anti-CCNB1. b Immunohistochemical stainings
. c Immuno-histochemical stainings of five Urobasal A cases (1–5) and
t Ser10. d Bee-swarm dot-plots showing the distribution of division
al vs. GU/SCCL tumors. Red lines indicate median angle for each group.
mors and in Urobasal vs. SCCL tumors (red lines) plotted against the
al size
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(p < 10−8), epithelium development (p < 10−6), and uro-
genital system development (p < 10−4), and included
the genes TP63, GATA3, TBX3, ELF3, BMP7, TGFBR2,
TGFBR3, SMAD3 and SMAD6, all with documented
roles in differentiation and developmental processes.
Urobasal A tumors show basal membrane associated cell
divisions
IHC analyses of CNNB1 expression in paraffin embed-
ded material revealed a large proportion of G2/M cells
located close to basal membranes. These observations
were particularly evident in low grade Urobasal tumors.
Furthermore, a large proportion of the CCNB1 positive
cells were in contact with the basal membrane (Fig. 7a).
By rescreening slides stained with antibodies for PLK1,
also a G2/M specific marker, similar structures were ob-
served as well as occasional cells with metaphase struc-
tures attached to the basal membrane (Fig. 7b). To
obtain a more direct visualization of dividing cells we
applied an antibody for phosphorylated histone H3
(Ser10) (Fig. 7c). The phospho-HISTH3 antibody con-
firmed that cell divisions were localized to predomin-
antly basal and suprabasal cell layers and frequently
were in contact with the basal membrane in UroA cases.
We next identified 416 phospho-HISTH3 positive mi-
totic structures and measured the division angle relative
to the nearest basal membrane. This investigation
showed enrichment for division angles close to 90° when
in close proximity to the basal membrane in low grade
and UroA tumors (Fig. 7d-e). Thus, the distribution of cell
division angles suggest that basal asymmetric cell divisions
occur preferentially in UroA and low grade tumors, a pat-
tern reminiscent of the regulated proliferation of normal
urothelium.
Discussion
The RXRA receptor protein forms heterodimers with
the peroxisome proliferator-activated receptor-gamma
(PPARG) and with retinoic acid receptors (RARs). Activation
of PPARG and RAR both induce urothelial differenti-
ation and expression of terminal differentiation genes
[36, 37]. Knockdown of GATA4 and GATA6 abrogates
the induction of UPK genes, showing that the GATA
family of transcription factors acts as mediators of the
RAR/RXRA induced response [36]. In addition, GATA4
and GATA6 as well as GATA2 and GATA3 show RXRA
and PPARG ChIP-Seq binding sites in their promoters.
PPARG/RXRA and RAR/RXRA signaling ultimately
leads to the induction of the regulatory factor FOXA1
[36, 23]. Hence, the RAR/PPARG/RXRA FOXA1/GATA
circuit shows strong involvement in differentiation of
the normal urothelium. Our findings show that PPARG,
RXRA, FOXA1 and GATA3 were strongly downregulatedin the SCC-like tumors. Although RAR expression did not
vary between subtypes, RA signaling may still be impaired
as ALDH1A2 was downregulated and CYP26B1 was upreg-
ulated in the SCCL subtype. Additional downregulated
factors potentially activated by the PPARG/RXRA/RAR sys-
tem included ELF3, TBX2 and TBX3 [22, 38, 39]. Methyla-
tion of TBX2 and TBX3 has been found to be associated
with urothelial tumor progression [40], however their full
role in urothelial carcinoma is not yet clear. PPARG regu-
lates the balance between glucose and lipid oxidation [41]
and drives differentiation through a metabolic shift to lipid
metabolism in prostate epithelia [42]. A key player in this
process may be the transcription/nuclear factor ADIRF. Lit-
tle is known about this factor except that it acts upstream
of PPARG in lipid metabolism regulation [26]. Hence,
downregulation of PPARG and ADIRF may contribute to
an undifferentiated basal cell state by inhibiting lipid metab-
olism. STAT3 showed increased protein expression and
phosphorylation in SCCL tumors. The importance of
STAT3 in transforming normal urothelium to carcinoma in
situ has been elegantly shown in transgenic mouse models
[43]. The keratinizing squamous phenotype that character-
izes the SCCL subtype may be a consequence of altered
PPARG levels, as coordinated downregulation of PPARG
and PTEN induces squamous differentiation of urothelium
[44]. Conversely, activation of PPARG and inactivation of
EGFR signaling reverses squamous metaplasia and induces
urothelial differentiation [45]. Hence, downregulation of
PPARG/RXRA and high EGFR expression combined with
phospho-activation of STAT3 in SCCL UC most likely con-
tribute to a basal/SCC-like phenotype and suggest that the
SCCL subtype has a block in the normal differentiation of
the urothelium.
Our analyses highlighted FOXM1 and members of the
E2F family to have key roles in determining the GU and
SCCL phenotypes. The roles of E2F transcription factors
and their interactions with RB related proteins in cell
cycle regulation is well established and we have de-
scribed a RB1/E2F3 genomic circuit specifically operat-
ing in the GU subtype of tumors [6]. FOXM1
accumulates during the cell cycle but is kept in an in-
active state by autorepression. At G2 FOXM1 is relieved
from repression by CCNA/CDK phosphorylation and a
positive feedback loop with PLK1 ensures hyperactiva-
tion of FOXM1 that ultimately triggers the G2 to M
transition [31]. Our data show that FOXM1 and PLK1
protein expression levels are strongly associated in UC
and that the PLK1-FOXM1 axis is activated in GU and
SCCL cases. Activated FOXM1 binds to the DREAM
transcription factor complex necessary for completion of
the cell cycle [46]. Hence, the colocalization of FOXM1
ChIP-Seq binding sites with ChIP-Seq binding sites for
members of the DREAM transcription factor complex in
the identified gene signature strongly suggests that
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the GU and SCCL subtypes. FOXM1 also influences cel-
lular differentiation. Loss of FOXM1 expression in mam-
mary glands leads to an increase in the number of
differentiated cells whereas FOXM1 overexpression re-
sults in expansion of undifferentiated cells, suggesting
that FOXM1 expressing cells fail to exit the progenitor
cell pool and to differentiate properly [47]. FOXM1 is
also upregulated during regeneration in response to in-
jury and may be required for the expansion of regenera-
tive stem/progenitor cells [48]. In addition, FOXM1
overexpression has been linked with tumor aggressive-
ness [49] and with the accumulation of genomic alter-
ations [50]. This latter finding is in accordance with the
more complex genomes seen in GU and SCCL tumors
[6]. Taken together, our data suggest the PLK1-FOXM1
axis as a key player in urothelial carcinoma biology by
regulating a dynamic switch from a differentiated non-
proliferative state to a proliferative undifferentiated state.
This suggests that differentiation in GU is bypassed, not
blocked, explaining why advanced high grade GU tu-
mors frequently express differentiation markers, albeit in
an aberrant way [4, 51].
UroA tumors showed maintained PPARG, RXRA,
FOXA1 and GATA3 protein expression in the majority
of cases. This likely contributes to the differentiated
phenotype seen in this subtype. The link between
PPARG expression and UroA, i.e., low-grade stage Ta tu-
mors, has also been suggested by Biton et al. [52]. Even
though GU tumors frequently express subsets of the
same proteins, GU tumors rarely express the complete
set. This impairment may be linked to elevated FOXM1
expression as FOXM1 is known to abrogate GATA3Fig. 8 Regulatory systems operating in UC subtypes. Schematic summary o
subtypes, as suggested by the present findingsactivity [47] and GATA3 was the most frequently down-
regulated protein of this set of proteins in GU. We noted
sharp shifts of positive to negative FABP4/CRABP2 and
FABP5/CRABP2 gene expression ratios in GU cases.
The ratio of FABP5 and CRABP2 expression is crucial
for fatty acid ligand shuttling and ultimately affects cell
fate [33, 34]. Hence, even if GU cases may express the
luminal associated PPARG [53], this protein is expressed
in a completely different context in GU compared with
UroA.
In experimental systems undifferentiated cells express
the posterior HOXA genes while RA differentiated cells
express the anterior HOXA genes [54] creating an
“anterior” signature in differentiated and a “posterior”
signature in undifferentiated cells [55]. In our data the
anterior signature was prevalent in UroA, the subtype
with the most explicit signs of differentiation i.e., low
pathological grade, largely maintained urothelial like
histology and occasional luminal expression of UPKs [4].
Furthermore, anterior HOXA and HOXB gene pro-
moters have abundant PPARG, RXRA, FOXA1, GATA3,
as well as with RARA protein binding sites. Hence, we
propose a gene regulatory link between the PPARG/
RXRA and FOXA1/GATA3 systems and anterior HOXA
and HOXB expression. Using ChIP-Seq data for mouse
HOXA2 we showed that several genes important for
urothelial differentiation, upregulated in UroA, were po-
tentially HOXA2 regulated. These genes included the
transcription factors GATA3, ELF3 and TP63 required
for urothelial stratification [56], and members of the
TGFB signaling pathway. Hence, the presented data de-
lineates a differentiation program involving PPARG/
RXRA as well as anterior HOXA and HOXB genes thatf the gene regulatory systems operating in urothelial carcinoma
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rated in GU and is downregulated in SCCL tumors.
We [4], and others [7, 53, 57], have noted the analogy
between the urothelial carcinoma SCCL subtype and the
breast cancer basal-like subtype. Apart from the fact that
the role of the PPARG/RXRA heterodimer in urothelial
cancer is exchanged with the ESR1 hormone receptor in
breast cancer, the key transcription factors FOXA1 and
GATA3 are downregulated in the basal/SCC-like sub-
types of both tumor types. Furthermore, there is ample
evidence that both FOXA1 and GATA3 have key roles
in luminal epithelial mammary differentiation [58, 59].
Altered lipid metabolism seems to be a key feature in es-
tablishing the SCCL UC and basal-like BC subtypes. The
role of the regulatory factor ADIRF in this process, how-
ever, remains to be established. The similarities also in-
cluded breast cancer basal-like upregulated genes which
were, as in UC, enriched for STAT3 binding in their pro-
moters. The analogy could also be extended to the lung
squamous cell carcinoma subtype and suggests that
downregulation of FOXA1 and GATA3 as well as upreg-
ulation/activation of EGFR and STAT3 as fundamental
components of a generalized basal/squamous-like tumor
phenotype. Although to a lesser extent, the similarities
between UC and BC subtypes may be extended to in-
clude the Genomically Unstable and Urobasal subtypes
as well. In this respect Genomically Unstable would be
analogous to the Luminal B and HER2-enriched sub-
types characterized by being aggressive, undifferentiated
and PLK1-FOXM1 driven and the Urobasal subtype
analogous to Luminal A as both show dependence of
nuclear hormone receptors for their phenotypes. Thus,
tumor types as disparate as bladder and breast cancer
may be determined by analogous underlying regulatory
systems even though the resulting phenotype and tissue
of origin may differ.
Conclusions
The emerging picture is that Urobasal, Genomically Un-
stable and SCC-like subtypes of urothelial carcinoma
represent three fundamentally different tumor types
(summarized in Fig. 8). Urobasal tumors maintain the
suggested urothelial differentiation axis composed of
PPARG/RXRA, FOXA1/GATA3 and HOXA/HOXB genes
more or less intact. Furthermore, our data indicate that a
large proportion of cell divisions in low grade Urobasal tu-
mors are associated with the basal membrane, possibly giv-
ing rise to asymmetrical divisions. A critical difference
between the Urobasal and the Genomically Unstable and
SCC-like tumors, is an increase of proliferative activity
independent of a basal membrane. The elevated prolifera-
tive activity was observed as a strong signal for PLK1-
FOXM1 regulated genes in both subtypes. However,
whereas SCC-like tumors seem to have a block inurothelial differentiation, the Genomically Unstable tu-
mors appear to evade differentiation in a more dynamic
manner, potentially through the action of FOXM1. Core
components of the described regulatory systems appeared
to operate across multiple tumor types such as breast and
lung cancer. Even though the presented exploratory data is
suggestive, the assumptions have to be validated in experi-
mental systems. Irrespectively, our data point to major dif-
ferences at the gene regulatory level between urothelial
carcinoma subtypes.
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